Anti-Human EGFR VHH Single Domain Antibody is a recombinant protein produced in E. coli.
Figure 1 Functional characterization of purified EgA1 ATTACK.
Biolayer interferometry (BLI)-derived sensorgrams (in black) for the interaction between immobilized EGFR-Fc and EgA1-based antibodies.
Harwood, S. L., Alvarez-Cienfuegos, A., Nuñez-Prado, N., Compte, M., Hernández-Pérez, S., Merino, N., ... & Mikkelsen, K. (2018). ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology, 7(1), e1377874.
Figure 2 Functional characterization of purified EgA1 ATTACK.
The binding to EGFR on the cell surface of HeLa cells by cetuximab- and EgA1-based antibodies at 0.1, 0.32, 1, and 10 nM, measured by FACS and normalized to the binding at 10 nM.
Harwood, S. L., Alvarez-Cienfuegos, A., Nuñez-Prado, N., Compte, M., Hernández-Pérez, S., Merino, N., ... & Mikkelsen, K. (2018). ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology, 7(1), e1377874.
Figure 3 Functional characterization of purified EgA1 ATTACK.
The binding to CD3 on the cell surface of Jurkat cells by OKT3- and EgA1-based antibodies at 0.1, 1, 3.2, and 10 nM, measured by FACS and normalized to the binding at 10 nM.
Harwood, S. L., Alvarez-Cienfuegos, A., Nuñez-Prado, N., Compte, M., Hernández-Pérez, S., Merino, N., ... & Mikkelsen, K. (2018). ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology, 7(1), e1377874.
Figure 4 EGa1-L cause a massive sequestration of cell surface EGFR.
Immediately after a 4 h incubation, cells were collected and stained for cell surface EGFR.
Oliveira, S., Schiffelers, R. M., van der Veeken, J., van der Meel, R., Vongpromek, R., en Henegouwen, P. M. V. B., ... & Roovers, R. C. (2010). Downregulation of EGFR by a novel multivalent sdAb-liposome platform. Journal of Controlled Release, 145(2), 165-175.
Figure 5 EGa1-L induce downregulation of EGFR. 14C cells were incubated for 4 h at 37 °C with liposomes containing two different ratios of sdAb to TL (0.4 and 0.8 nmol/ μmol TL) at 0.5 mM TL concentration.
Ratio's of the intensity of EGFR bands normalized to β-actin bands (non-treated set to 100%), from three independent experiments, are shown for lysates prepared after 2 days of chase following the 4 h pulse incubation.
Oliveira, S., Schiffelers, R. M., van der Veeken, J., van der Meel, R., Vongpromek, R., en Henegouwen, P. M. V. B., ... & Roovers, R. C. (2010). Downregulation of EGFR by a novel multivalent sdAb-liposome platform. Journal of Controlled Release, 145(2), 165-175.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-750 | Anti-EGFR/HER1 Recombinant Antibody (Futuximab/Zatuximab) | Neut, ELISA, IF, IP, FuncS, FC, WB | IgG1 - kappa |
TAB-H35 | Anti-Human EGFR Recombinant Antibody (Futuximab) | IF, WB, Inhib | IgG1 - kappa |
TAB-308MZ | Human Anti-EGFR Recombinant Antibody (TAB-308MZ) | FuncS | Chimeric antibody (mouse/human) |
TAB-302MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-302MZ-S(P)) | ELISA | Mouse scFv |
TAB-308MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-308MZ-S(P)) | ELISA, FC | Mouse scFv |
There are currently no Customer reviews or questions for PNBL-018. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.